Clinical Trial Update: 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for 131I-omburtamab in neuroblastoma with CNS/leptomeningeal metastases shows terminated status with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cns Metastases
• Leptomeningeal Metastases
• Neuroblastoma

Drugs mentioned

• 131I-omburtamab (omburtamab)

Snippet

Sponsor: Y-mAbs Therapeutics | Conditions: Neuroblastoma, CNS Metastases | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-02-13